Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...
Inquirer on MSN2d
Ketamine a lifeline for severe depression patients in SingaporeKetamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...
Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its ...
US Weekly on MSN6d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, MoreCelebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback